However, according to the results of a phase Ib/IIa clinical study, no evidence of anti-inflammatory, anticoagulant, or antiviral activity of intravenous nafamostat in hospitalized COVID-19 patients was provided.611 The negative outcomes of the abovementioned TMPRSS2 inhibitors raise questions about the effectiveness of this target. This evidence concerns the gene TMPRSS2 and COVID-19.